請用此 Handle URI 來引用此文件：
http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/51303完整後設資料紀錄
| DC 欄位 | 值 | 語言 |
|---|---|---|
| dc.contributor.advisor | 張雅珮,蘇璧伶 | |
| dc.contributor.author | Chih-Ching Wu | en |
| dc.contributor.author | 吳芝菁 | zh_TW |
| dc.date.accessioned | 2021-06-15T13:29:56Z | - |
| dc.date.available | 2021-02-24 | |
| dc.date.copyright | 2016-02-24 | |
| dc.date.issued | 2016 | |
| dc.date.submitted | 2016-02-04 | |
| dc.identifier.citation | 1. Barnoon I, Shamir M, Aroch I, Bdolah‐Abram T, Srugo I, Konstantin L, et al. Retrospective evaluation of combined mycophenolate mofetil and prednisone treatment for meningoencephalomyelitis of unknown etiology in dogs: 25 cases (2005–2011). J Vet Emerg Crit Car. 2016;26(1):116-124.
2. Lowrie M, Smith PM, Garosi L. Meningoencephalitis of unknown origin: investigation of prognostic factors and outcome using a standard treatment protocol. Vet Rec. 2013;172(20):527. 3. Tipold A. Diagnosis of Inflammatory and Infectious Diseases of the Central Nervous System in Dogs: A Retrospective Study. J Vet Intern Med. 1995;9(5):304–314. 4. Munana KR, Luttgen PJ. Prognostic factors for dogs with granulomatous meningoencephalomyelitis: 42 cases (1982-1996). J Am Vet Med Assoc. 1998 ;212(12):1902–1906. 5. Braund KG. Granulomatous meningoencephalomyelitis. J Am Vet Med Assoc. 1985;186(2):138–141. 6. Granger N, Smith PM, Jeffery ND. Clinical findings and treatment of non-infectious meningoencephalomyelitis in dogs: a systematic review of 457 published cases from 1962 to 2008. Vet J. 2010;184(3):290–297. 7. Coates J, Barone G, Dewey C, Vitale C, Holloway‐Azene N, Sessions J. Procarbazine as Adjunctive Therapy for Treatment of Dogs with Presumptive Antemortem Diagnosis of Granulomatous Meningoencephalomyelitis: 21 Cases (1998–2004). J Vet Intern Med. 2007;21(1):100–106. 8. Garmer NL, Naeser P, Bergman AJ. Reticulosis of the eyes and the central nervous system in a dog. J Small Anim Pract. 1981;22(1):39–45. 9. Smith JS, deLahunta A, Riis RC. Reticulosis of the visual system in a dog. J Small Anim Pract. 1977;18(10):643–652. 10. Zarfoss M, Schatzberg S, Venator K, Cutter-Schatzberg K, Cuddon P, Pintar J, et al. Combined cytosine arabinoside and prednisone therapy for meningoencephalitis of unknown aetiology in 10 dogs. J Small Anim Pract. 2006;47(10):588–595. 11. Talarico L, Schatzberg S. Idiopathic granulomatous and necrotising inflammatory disorders of the canine central nervous system: a review and future perspectives. J Small Anim Pract. 2010;51(3):138–149. 12. Barber RM, Porter BF, Li Q, May M, Claiborne MK, Allison AB, et al. Broadly Reactive Polymerase Chain Reaction for Pathogen Detection in Canine Granulomatous Meningoencephalomyelitis and Necrotizing Meningoencephalitis. J Vet Intern Med. 2012;26(4):962–968. 13. Kipar A, Baumgartner W, Vogl C, Gaedke K, Wellman M. Immunohistochemical Characterization of Inflammatory Cells in Brains of Dogs with Granulomatous Meningoencephalitis. Vet Pathol. 1998;35(1):43–52. 14. O’Neill E, Merrett D, Jones B. Granulomatous meningoencephalomyelitis in dogs: A review. Irish Vet J. 2005;58(2):86–92. 15. Sorjonen DC. Clinical and histopathological features of granulomatous meningoencephalomyelitis in dogs. Journal of the American Animal Hospital Association. 1990;26(2):141–147. 16. Fankhauser R, Fatzer R, Luginbuhl H. Reticulosis of the central nervous system (CNS) in dogs. Adv Vet Sci Comp Med. 1972;16:35–71. 17. Braund KG, Vandevelde M, Walker TL, Redding RW. Granulomatous meningoencephalomyelitis in six dogs. J Am Vet Med Assoc. 1978;172(10):1195–1200. 18. Suzuki M, Uchida K, Morozumi M, Yanai T, Nakayama H, Yamaguchi R, et al. A Comparative Pathological Study on Granulomatous Meningoencephalomyelitis and Central Malignant Histiocytosis in Dogs. J Vet Med Sci. 2004;65(12):1319–1324. 19. Park E, Uchida K, Nakayama H. Comprehensive immunohistochemical studies on canine necrotizing meningoencephalitis (NME), necrotizing leukoencephalitis (NLE), and granulomatous meningoencephalomyelitis (GME). Vet Pathol. 2012;49(4):682–92. 20. Tipold A, Moore P, Zurbriggen A, Vandevelde M. Lymphocyte subset distribution in steroid responsive meningitis-arteriitis in comparison to different canine encephalitides. Zentralbl Veterinarmed A. 1999 Mar 1;46(2):75–85. 21. Goverman J. Autoimmune T cell responses in the central nervous system. Nat Rev Immunol. 2009;9(6):393–407. 22. Flegel T, Oevermann A, Oechtering G, Matiasek K. Diagnostic yield and adverse effects of MRI-guided free-hand brain biopsies through a mini-burr hole in dogs with encephalitis. J Vet Intern Med. 2012;26(4):969–976. 23. Koblik PD, LeCouteur RA, Higgins RJ, Bollen AW, Vernau KM, Kortz GD, et al. CT-guided brain biopsy using a modified Pelorus Mark III stereotactic system: experience with 50 dogs. Vet Radiol Ultrasound. 1999;40(5):434–440. 24. Chen AV, Wininger FA, Frey S, Comeau RM, Bagley RS, Tucker RL, et al. Description and validation of a magnetic resonance imaging-guided stereotactic brain biopsy device in the dog. Vet Radiol Ultrasound. 2012;53(2):150–156. 25. Cherubini G, Platt S, Anderson T, Rusbridge C, Lorenzo V, Mantis P, et al. Characteristics of magnetic resonance images of granulomatous meningoencephalomyelitis in 11 dogs. Vet Rec. 2006;159(4):110–115. 26. Kitagawa M, Kanayama K, Satoh T, Sakai T. Cerebellar focal granulomatous meningoencephalitis in a dog: clinical findings and MR imaging. J Vet Med A Physiol Pathol Clin Med. 2004;51(6):277–279. 27. Kitagawa M, Okada M, Watari T, Sato T, Kanayama K, Sakai T. Ocular granulomatous meningoencephalomyelitis in a dog: magnetic resonance images and clinical findings. J Vet Med Sci. 2009;71(2):233–237. 28. Pakozdy, Leschnik, Kneissl, Gumpenberger, Gruber, Tichy, et al. Improved survival time in dogs with suspected GME treated with ciclosporin. Vet Rec. highwire; 2009;164(3):89–90. 29. Flegel T, Boettcher I, Matiasek K, Oevermann A, Doherr M, Oechtering G, et al. Comparison of oral administration of lomustine and prednisolone or prednisolone alone as treatment for granulomatous meningoencephalomyelitis or necrotizing encephalitis in dogs. J Am Vet Med Assoc. 2011;238(3):337–345. 30. Gnirs K. Ciclosporin treatment of suspected granulomatous meningoencephalomyelitis in three dogs. J Small Anim Pract. 2006;47(4):201–206. 31. Adamo P, Rylander H, Adams W. Ciclosporin use in multi‐drug therapy for meningoencephalomyelitis of unknown aetiology in dogs. J Small Anim Pract. 2007;48(9):486–496. 32. Jung DI, Kang BT, Park C, Yoo JH, Gu SH, Jeon HW, et al. A Comparison of Combination Therapy (Cyclosporine plus Prednisolone) with Sole Prednisolone Therapy in 7 Dogs with Necrotizing Meningoencephalitis. J Vet Med Sci. 2008;69(12):1303–1306. 33. Menaut P, Landart J, Behr S, Lanore D, Trumel C. Treatment of 11 dogs with meningoencephalomyelitis of unknown origin with a combination of prednisolone and cytosine arabinoside. Vet Rec. 2008;162(8):241–245. 34. Adamo F, O’Brien R. Use of cyclosporine to treat granulomatous meningoencephalitis in three dogs. J Am Vet Med Assoc. 2004;225(8):1211–1216. 35. Wong MA, Hopkins AL, Meeks JC, Clarke JD. Evaluation of treatment with a combination of azathioprine and prednisone in dogs with meningoencephalomyelitis of undetermined etiology: 40 cases (2000-2007). J Am Vet Med Assoc. 2010;237(8):929–35. 36. Smith PM, Stalin CE, Shaw D, Granger N, Jeffery ND. Comparison of two regimens for the treatment of meningoencephalomyelitis of unknown etiology. J Vet Intern Med. 2009;23(3):520–6. 37. Bateman SW, Parent JM. Clinical findings, treatment, and outcome of dogs with status epilepticus or cluster seizures: 156 cases (1990-1995). J Am Vet Med Assoc. 1999;215(10):1463–1468. 38. Gause WC, Lu P, Zhou XD, Chen SJ, Madden KB, Morris SC, et al. H. polygyrus: B7-independence of the secondary type 2 response. Exp Parasitol. 1996;84(2):264–73. 39. Mellman I, Steinman RM. Dendritic cells: specialized and regulated antigen processing machines. Cell. 2001;106(3):255–8. 40. Antel JP, Owens T. Neuroimmunology. Wiley Online Library; 2005. 41. Phillips M, Needham M, Weller R. Role of cervical lymph nodes in autoimmune encephalomyelitis in the Lewis rat. J Pathology. 1997;182(4):457–464. 42. Lake J, Weller R, Phillips M, Needham M. Lymphocyte targeting of the brain in adoptive transfer cryolesion-EAE. J Pathology. 1999;187(2):259–265. 43. Zwam M, Huizinga R, Heijmans N, Meurs M, Wierenga‐Wolf A, Melief M, et al. Surgical excision of CNS‐draining lymph nodes reduces relapse severity in chronic‐relapsing experimental autoimmune encephalomyelitis. J Pathology. 2009;217(4):543–551. 44. Vos A, Meurs M, Brok H, Boven L, Hintzen R, Valk P, et al. Transfer of central nervous system autoantigens and presentation in secondary lymphoid organs. J Immunol Baltim Md 1950. 2002;169(10):5415–5423. 45. Groothuis DR, Vavra MW, Schlageter KE, Kang EW, Itskovich AC, Hertzler S, et al. Efflux of drugs and solutes from brain: the interactive roles of diffusional transcapillary transport, bulk flow and capillary transporters. J Cereb Blood Flow Metab. 2007;27(1):43–56. 46. Thrane V, Thrane AS, Plog BA, Thiyagarajan M, Iliff JJ, Deane R, et al. Paravascular microcirculation facilitates rapid lipid transport and astrocyte signaling in the brain. Scientific reports. 2013;3. 47. Johnston M, Zakharov A, Koh L, Armstrong D. Subarachnoid injection of Microfil reveals connections between cerebrospinal fluid and nasal lymphatics in the non-human primate. Neuropathol Appl Neurobiol. 2005 Dec 4;31(6):632–640. 48. Leeds SE, Kong AK, Wise BL. Alternative pathways for drainage of cerebrospinal fluid in the canine brain. Lymphology. 1989;22(3):144–146. 49. Kaminski M, Bechmann I, Pohland M, Kiwit J, Nitsch R, Glumm J. Migration of monocytes after intracerebral injection at entorhinal cortex lesion site. Journal of leukocyte biology. 2012;92(1):31–39. 50. Goldmann J, Kwidzinski E, Brandt C, Mahlo J, Richter D, Bechmann I. T cells traffic from brain to cervical lymph nodes via the cribroid plate and the nasal mucosa. J Leukoc Biol. 2006;80(4):797–801. 51. Schwartz M, Raposo C. Protective Autoimmunity: A Unifying Model for the Immune Network Involved in CNS Repair. Neuroscientist. 2014;20(4):343–358. 52. Louveau A, Smirnov I, Keyes TJ, Eccles JD, Rouhani SJ, Peske JD, et al. Structural and functional features of central nervous system lymphatic vessels. Nature. 2015;523(7560):337–341. 53. Louveau A, Harris T, Kipnis J. Revisiting the Mechanisms of CNS Immune Privilege. Trends Immunol. 2015;36(10):569–577. 54. Laman JD, Weller RO. Drainage of cells and soluble antigen from the CNS to regional lymph nodes. J Neuroimmune Pharmacol. 2013;8(4):840–856. 55. Weller RO, Galea I, Carare RO, Minagar A. Pathophysiology of the lymphatic drainage of the central nervous system: Implications for pathogenesis and therapy of multiple sclerosis. Pathophysiology. 2010;17(4):295–306. 56. Weller RO, Djuanda E, Yow H-YY, Carare RO. Lymphatic drainage of the brain and the pathophysiology of neurological disease. Acta Neuropathol. 2009;117(1):1–14. 57. Saad E, Katz A, Hoff P, Buyse M. Progression-free survival as surrogate and as true end point: insights from the breast and colorectal cancer literature. Ann Oncol. 2010;21(1):7–12. 58. Pazdur R. Endpoints for Assessing Drug Activity in Clinical Trials. Oncol. 2008;13(Supplement 2):19–21. 59. Bradburn MJ, Clark TG, Love SB, Altman DG. Survival analysis part II: multivariate data analysis–an introduction to concepts and methods. Br J Cancer. 2003;89(3):431-436 60. Begley D. Delivery of therapeutic agents to the central nervous system: the problems and the possibilities. Pharmacol Therapeut. 2004;104(1):29–45. 61. Raskin RE, Meyer D. Canine and feline cytology: a color atlas and interpretation guide. Elsevier Health Sciences; 2015. 62. Schwab S, Herden C, Seeliger F, Papaioannou N, Psalla D, Polizopulou Z, et al. Non-suppurative meningoencephalitis of unknown origin in cats and dogs: an immunohistochemical study. J Comp Pathol. 2007;136(2):96–110. 63. O’Malley DP. Benign and reactive conditions of lymph node and spleen. ARP Press; 2009. 64. Fiore-Donati L, Hanna MG. Lymphatic tissue and germinal centers in immune response: proceedings. Plenum Press; 1969. 65. Gruver-Yates A, Quinn M, Cidlowski J. Analysis of glucocorticoid receptors and their apoptotic response to dexamethasone in male murine B cells during development. Endocrinology. 2013;155(2):463–474. 66. Purton JF, Monk JA, Liddicoat DR, Kyparissoudis K, Sakkal S, Richardson SJ, et al. Expression of the glucocorticoid receptor from the 1A promoter correlates with T lymphocyte sensitivity to glucocorticoid-induced cell death. J Immunol. 2004;173(6):3816–3824. 67. Lim JH, Kim JS, Yoon IH, Shin JS, Nam HY, Yang SH, et al. Immunomodulation of delayed-type hypersensitivity responses by mesenchymal stem cells is associated with bystander T cell apoptosis in the draining lymph node. J Immunol. 2010;185(7):4022–4029. 68. Hunter S, Bowen J, Reder A. The Direct Effects of Fingolimod in the Central Nervous System: Implications for Relapsing Multiple Sclerosis. Cns Drugs. 2015; 69. Fillatreau S, Sweenie CH, McGeachy MJ, Gray D, Anderton SM. B cells regulate autoimmunity by provision of IL-10. Nature immunology. 2002;3(10):944–950. 70. Felix A, Guiot EG, Stein M, Felix SR, Silva EF, Nobre MO. Comparison of systemic interleukin 10 concentrations in healthy dogs and those suffering from recurring and first time Demodex canis infestations. Vet parasitol. 2013;193(1):312–5. | |
| dc.identifier.uri | http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/51303 | - |
| dc.description.abstract | 犬肉芽腫性腦膜腦脊髓炎（granulomatous meningoencephalomyelitis，GME）是犬中樞神經一種常見的發炎性疾病。GME好發於壯年至中年的玩具與小型犬種，GME特徵病理變化為中樞神經白質為主，發炎細胞以血管為中心同心圓式聚集，病理變化可以彌散發生在灰白質內，也可能形成明顯的肉芽腫團塊。目前GME的致病機轉仍不明，但懷疑是一種與T型淋巴球為主的遲發過敏反應相關的自體免疫疾病。由於GME需經過組織病理學檢查確診，因此多為死後診斷，或需經腦採樣取得檢體，後者目前臨床使用的普遍性不高，實用性較低，因此在生前診斷GME仰賴病患符合幾項特徵：好發族群、腦脊髓液與進階神經影像變化，並排除其他感染性疾病，皆符合者稱為生前診斷GME患者。
GME若不經積極治療預後不佳，且病程可能進展快速，文獻指出約有15%患犬發病後尚未接受治療即死亡。為了瞭解GME的危險因子，並比較臺大附設動物醫院常用的以類固醇為基礎的3種免疫抑制療法（cytosine arabinoside、mycophenolate mofetil、cyclsporin)，本研究收集臺大附設動物醫院自2007年至2014年經生前或死後確診的GME病患資料共77隻，分析其影響生存時間的危險因子；因GME進入慢性病程後需長期用藥，因此藥物累積性副作用、飼主對長期用藥的偏好與經濟考量、病患對藥物適應程度等多種因素都可能影響藥物選擇與使用，為減少這些因素的影響，故採取無進展生存期（progression free survival，PFS）作為評估3種免疫治療的替代終點。危險因子分析結果發現，延後治療（神經症狀出現21到42天）、就診時神經症狀包含癲癇、無法行走、有叢集或重積癲癇的病史以及治療期間發生脊椎旁壓痛等，皆為生存時間的顯著危險因子。當用多因子統計法同時考量其他影響PFS的因素後，cyclosporin在延長PFS上較另外兩種免疫抑制劑表現佳。在早期復發的病患中，若能使用多種免疫抑制療法，則可顯著增長其存活時間。 然而在積極治療下，仍有36%病患存活期無法超過一年，10%病患在入院一個月內死亡。為了從不同的角度研究此疾病，本研究第二部分對引流中樞神經的深頸淋巴結進行前導研究，以組織化學染色方式分析GME患犬深頸淋巴結的淋巴球形態與分佈，結果發現GME患犬淋巴結出現Ｔ淋巴球增多與Ｂ淋巴球大量減少，懷疑此變化與患犬中樞神經發炎反應有關，值得更進一步研究周邊免疫系統在調控或維持中樞神經發炎中是否扮演部分角色。 | zh_TW |
| dc.description.abstract | Canine granulomatous meningoencephalomyelitis (GME) is a common canine inflammatory central nervous system (CNS) disease. It was yet unknown the etiology of GME and the theory suggesting its association with the T-cell delayed-type hypersensitivity is generally accepted.
If left untreated, the prognosis of GME is poor. In order to identify the risk factors and to evaluate treatment efficacy between 3 different adjunctive immunosuppressants (cytosine arabinoside, mycophenolate mofetil, and cyclosporin) on canine antemortem or postmortem diagnosed GME, a retrospective study reviewing medical records of canine GME patients in National Taiwan University Veterinary Hospital between January 2008 and December 2014 was performed. A total of 77 dogs were included. Since the clinical conditions became more diverted with time under various confounding factors, progression free survival (PFS) was used as a surrogate endpoint instead of overall survival time (OST) for treatment efficacy comparison. Risk factors of OST and PFS were calculated separately. Delayed admission after the onset of neurologic signs (21-42 days), seizure, mentation change at presentation, non-ambulation, history of status epilepticus or cluster seizure, latent onset of spinal pain had significant influence on overall survival time (OST). With other significant risk factors of PFS calculated in a multivariate model, cyclsporin had the best efficacy among these 3 immunosuppressants. Multiple immunosuppressive therapy significantly increased OST in patients experiencing early relapses. Despite deploying collaborative immunosuppressive therapy, 36% of patients failed to achieve 1-year-survival and 10% died within 1 month. In hopes of approaching this disease from another angle, a primitive study on the CNS draining lymph nodes (LN) was undertaken. Immunohistochemical labeling reveals that those LNs had a marked expanded T-cell colony and diminished B-cell compartment, implicating a connection between the CNS and peripheral immune organs might exist in GME cases. | en |
| dc.description.provenance | Made available in DSpace on 2021-06-15T13:29:56Z (GMT). No. of bitstreams: 1 ntu-105-R01643014-1.pdf: 2627436 bytes, checksum: 857ef5fd8be3d75d2cf25af1478bb830 (MD5) Previous issue date: 2016 | en |
| dc.description.tableofcontents | CONTENTS
口試委員會審定書………………………………………………………………..# 致謝 i 中文摘要 iii ABSTRACT v CONTENTS vii LIST OF FIGURES x LIST OF TABLES xi Chapter 1 Introduction……………………………………………………..1 1.1 Literature Review - Granulomatous meningoencephalitis (GME) 2 1.1.1 Overview of GME…………………………………………….2 1.1.2 Neuropathology of GME……………………………………..3 1.1.3 Neurodiagnostic approach……………………………………5 1.1.3.1 Cerebrospinal fluid analysis…………………………..6 1.1.3.2 Neuroimaging…………………………………………6 1.1.4 Treatment……………………………………………………..7 1.1.5 Prognosis……………………………………………………...8 1.2 Literature review - The relationship between the CNS and peripheral immunity 9 1.2.1 Immune properties of the CNS………………………………..9 1.2.2 Interactions between the CNS and peripheral immunity……..10 Chapter 2 Retrospective study of antemortem and postmortem diagnosed GME 16 2.1 Aim 16 2.2 Materials and Methods 16 2.2.1 Case selection………………………………………………..16 2.2.2 Statistical analysis…………………………………………...18 2.3 Results 20 2.3.1 Signalment and clinical presentation………………………..20 2.3.2 Neuroanatomic localization…………………………………20 2.3.3 CSF analysis…………………………………………………21 2.3.4 Duration of neurologic signs and treatment before presenting to NTUVH………………………………………………………21 2.3.5 Overall survival time and risk factors analysis………………22 2.3.6 Scoring system for risk assessment at patient’s first presentation…………………………………………………23 2.3.7 Progression free survival…………………………………….23 2.3.8 Efficacy evaluation on 3 immunosuppressants………………24 2.3.9 Early progression and multidrug therapy.……………………25 Chapter 3 Immunohistochemical analysis of the CNS draining lymph nodes 26 3.1 Aim 26 3.2 Materials and Methods 26 3.2.1 Animals……………………………………………………...26 3.2.2 Immunohistochemistry……………………………………...26 3.3 Results 28 Chapter 4 Discussion 29 Chapter 5 Future work 36 FIGURES………………………………………………………………………...37 TABLES…………………………………………………………………………..48 REFERENCE…………………………………………………………………….61 LIST OF FIGURES Figure 1 Distribution of clinical signs based on neuroanatomic localization for 77 dogs with presumptive antemortem and/or histologic diagnosed GME……………37 Figure 2 Distribution of CSF WBC count and total protein concentration for 77 dogs with presumptive antemortem and/or histologic diagnosed GME……………38 Figure 3 Kaplan-Meier estimate of overall survival time for dogs with a presumptive antemortem and or histologic diagnosed GME………………………………39 Figure 4 Kaplan-Meier estimate of progression free survival time for dogs with a presumptive antemortem and or histologic diagnosed GME…………………40 Figure 5 Kaplan-Meier estimate of overall survival time for dogs experienced early progression within 1 month………………………………………………….41 Figure 6 Immunohistochemical expression of CD79a, CD3, and MHC Class II in the deep cervical lymph node in dog A……………………………………….….42 Figure 7 Immunohistochemical expression of CD79a, CD3, and MHC Class II in the deep cervical lymph node in dog B ………………………………………….43 Figure 8 Immunohistochemical expression of CD79a, CD3, and MHC Class II in the deep cervical lymph node in dog C…………………………………………..44 Figure 9 Immunohistochemical expression of CD79a in dog E ……………………….45 Figure 10 Immunohistochemical expression of CD79a, and CD3 in the deep cervical lymph node in dog B …………………………………………………….…..46 Figure 11 Immunohistochemical expression of CD3 in deep cervical and popliteal lymph node in dog A………………………………………………………...………47 LIST OF TABLES Table 1 Univariate model of factors predictive of OST in Dogs with antemortem and postmortem diagnosed GME………………… ……………………………...48 Table 2 Multivariate model of factors predictive of OST in dogs with antemortem and postmortem diagnosed GME……… …………………………………….50 Table 3. Scoring formula of risk assessment at patient’s first presentation…………....51 Tabl3 4. The case count of and Cox regression for RR analysis in 3 risk groups of GME dogs…………………………………………………………………………..52 Table 5. Univariate model of factors predictive of PFS in dogs with antemortem and postmortem diagnosed GME……………………… ………………………..53 Table 6. Multivariate model of significant factors on PFS and 3 adjunctive immunosuppressants in dogs with antemortem and histologic diagnosed GME…………………………………………………………………………55 Table 7. Prednisolone dosages in dogs with antemortem and histopathologic confirmed GME that were treated with ArC, MMF or CiA………………………….….56 Table 8. Signalment, clinical signs, medication history, cause of death and histopathologic diagnosis of dogs in lymph node immunolabling study…….57 Table 9. Detailed immunohistochemistry antibodies and its target cells in the study….58 Table 10. The results of the immunohistocytochemistry study of the lymph nodes in the study………………………………………………………………………….59 Table 11. The ratio between cells stained positive of CD3, MHC II, and CD79a in canine lymph nodes………………………………………………… ………............60 | |
| dc.language.iso | en | |
| dc.subject | 免疫抑制藥物 | zh_TW |
| dc.subject | 中樞神經引流淋巴結 | zh_TW |
| dc.subject | 免疫抑制藥物 | zh_TW |
| dc.subject | 中樞神經引流淋巴結 | zh_TW |
| dc.subject | 危險因子 | zh_TW |
| dc.subject | 犬肉芽腫性腦膜腦脊髓炎 | zh_TW |
| dc.subject | 犬肉芽腫性腦膜腦脊髓炎 | zh_TW |
| dc.subject | 危險因子 | zh_TW |
| dc.subject | CNS draining lymph node | en |
| dc.subject | risk factor | en |
| dc.subject | mycophenolate mofetil | en |
| dc.subject | cytosine arabinoside | en |
| dc.subject | cyclosporin | en |
| dc.subject | CNS draining lymph node | en |
| dc.subject | canine granulomatous meningoencephalomyelitis | en |
| dc.subject | risk factor | en |
| dc.subject | mycophenolate mofetil | en |
| dc.subject | cytosine arabinoside | en |
| dc.subject | cyclosporin | en |
| dc.subject | canine granulomatous meningoencephalomyelitis | en |
| dc.title | 犬臨床和病理診斷肉芽腫性腦膜腦脊髓炎之回溯性調查與中樞神經引流淋巴結免疫染色表現 | zh_TW |
| dc.title | Canine antemortem and postmortem diagnosed granulomatous meningoencephalomyelitis: a retrospective study and immunohistochemical findings of CNS draining lymph nodes | en |
| dc.type | Thesis | |
| dc.date.schoolyear | 104-1 | |
| dc.description.degree | 碩士 | |
| dc.contributor.oralexamcommittee | 劉振軒,劉逸軒 | |
| dc.subject.keyword | 犬肉芽腫性腦膜腦脊髓炎,中樞神經引流淋巴結,免疫抑制藥物,危險因子, | zh_TW |
| dc.subject.keyword | canine granulomatous meningoencephalomyelitis,CNS draining lymph node,cyclosporin,cytosine arabinoside,mycophenolate mofetil,risk factor, | en |
| dc.relation.page | 66 | |
| dc.rights.note | 有償授權 | |
| dc.date.accepted | 2016-02-04 | |
| dc.contributor.author-college | 獸醫專業學院 | zh_TW |
| dc.contributor.author-dept | 臨床動物醫學研究所 | zh_TW |
| 顯示於系所單位： | 臨床動物醫學研究所 | |
文件中的檔案：
| 檔案 | 大小 | 格式 | |
|---|---|---|---|
| ntu-105-1.pdf 未授權公開取用 | 2.57 MB | Adobe PDF |
系統中的文件，除了特別指名其著作權條款之外，均受到著作權保護，並且保留所有的權利。